Hikma Pharmaceuticals USA Inc. manufactures and distributes prednisone, a corticosteroid medication. Prednisone is used to treat a wide range of conditions, including severe allergies, arthritis, breathing problems, certain types of cancer, eye problems, blood disorders, kidney problems, skin problems, and infections [1]. It works by reducing inflammation and suppressing the immune system [2].
What is Prednisone Used For?
Prednisone is prescribed for various inflammatory and autoimmune conditions. This includes treating severe allergic reactions, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD), and certain types of leukemia and lymphoma [1][3]. It is also utilized for conditions affecting the skin, eyes, kidneys, and gastrointestinal tract, such as inflammatory bowel disease [1].
How Does Prednisone Work?
As a corticosteroid, prednisone functions by mimicking the effects of hormones naturally produced by the adrenal glands. It exerts its therapeutic effects by binding to glucocorticoid receptors within cells, which then influences gene expression. This process leads to a reduction in the production of inflammatory mediators, such as cytokines and prostaglandins, thereby alleviating inflammation [2]. Additionally, prednisone can suppress immune cell activity, which is beneficial in treating autoimmune diseases where the immune system mistakenly attacks the body's own tissues [2][3].
When Does Prednisone Patent Expiry Occur?
Prednisone is a well-established medication, and its original patents have long since expired. This means that the active pharmaceutical ingredient itself is available as a generic drug from multiple manufacturers [4]. Hikma Pharmaceuticals USA Inc. manufactures a generic version of prednisone [1].
Can Biosimilars Enter Before Patent Expiry?
The concept of biosimilars applies to biologic medications, not small-molecule drugs like prednisone. Prednisone is a synthetic chemical compound, and its generic versions are available once the primary patents expire. Biosimilars are highly similar versions of approved biologic medicines, and their entry into the market is governed by different regulatory pathways and patent considerations than those for small-molecule drugs [5].